CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib

Clinical trial NCT01227577 · COMPLETED

Trial details

NCT number: NCT01227577
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Chronic Myelogenous Leukemia in Chronic Phase

Start date: 2010-11-01
Primary completion: 2014-11-01
Enrollment: 128

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.